UnitedHealth Q1 beat
- UnitedHealth reported stronger-than-expected Q1 results and raised its 2026 adjusted EPS outlook. - Management said improving cost control and margin repair drove the beat. - Investors reacted positively with shares rising and several analysts lifting price targets (thestreet.com).
UnitedHealth opened 2026 with a stronger quarter than Wall Street expected and lifted its full-year profit outlook on April 21. (unitedhealthgroup.com) The company reported first-quarter revenue of $111.7 billion, up 2% from a year earlier, with earnings of $6.90 a share and adjusted earnings of $7.23 a share. It raised its 2026 adjusted earnings forecast to more than $18.25 a share from more than $17.75 a share. (unitedhealthgroup.com) Analysts tracked by LSEG had expected adjusted profit of $17.86 a share for the full year, and Reuters reported the company’s new target was 50 cents above its prior outlook. Reuters also said the insurer benefited from tighter cost control and better government reimbursement in Medicare Advantage. (usnews.com) A key number for health insurers is the medical care ratio, the share of premium revenue spent on patient care. UnitedHealth said that ratio fell to 83.9% in the quarter from 84.8% a year earlier, a sign that claims costs eased after the industry’s Medicare Advantage squeeze since mid-2023. (unitedhealthgroup.com) That matters because UnitedHealth spent much of late 2025 trying to repair margins after a run of higher care use and operational strain. The company said its first-quarter performance reflected actions taken over the last several quarters, including changes in operations, management, technology and governance. (unitedhealthgroup.com) The stock jumped after the report. Schaeffer’s said UnitedHealth shares were up 9.3% to $353.66 in morning trading on April 21, and CNBC reported the results helped lift other managed-care stocks as investors looked for signs that Medicare Advantage costs were stabilizing. (schaeffersresearch.com) (cnbc.com) Some analysts moved quickly to raise targets. Benzinga reported Oppenheimer’s Michael Wiederhorn kept an outperform rating and lifted his price target to $405 from $385 after the earnings release. (benzinga.com) UnitedHealth’s own release showed the turnaround is not just about insurance pricing. Operating cash flow was $8.9 billion in the quarter, and the company said it plans to complete at least $2 billion of share repurchases by the end of the second quarter. (unitedhealthgroup.com) The next test is whether the lower medical cost ratio holds through the rest of 2026. For now, the first quarter gave UnitedHealth its clearest evidence yet that margin repair is showing up in reported earnings. (bloomberg.com)
